HOSPICE PALLIATIVE CARE PROGRAM

REFRACTORY SYMPTOMS AND PALLIATIVE SEDATION THERAPY GUIDE

Author(s): NH Hospice Palliative Care Consultation Team

Reorder #1824

Date: December 2012
# TABLE OF CONTENTS

How can Palliative Care help you manage difficult symptoms? What about refractory symptoms? .................................................................................................. 4  
Refractory Symptoms and Palliative Sedation Therapy ............................................ 5  
  Rationale ................................................................................................................... 5  
  Scope ....................................................................................................................... 5  
  Background ........................................................................................................... 5  
  Definition of terms .................................................................................................. 6  
    Palliative Care ........................................................................................................ 6  
    Refractory Symptoms .......................................................................................... 6  
    Difficult Symptoms ............................................................................................. 7  
    Suffering .............................................................................................................. 7  
    Existential Suffering ......................................................................................... 7  
    Moral Distress ..................................................................................................... 7  
    Natural Sedation ................................................................................................. 7  
    Consequential (ordinary/mild) Sedation .............................................................. 7  
    Respite Sedation ................................................................................................ 7  
    Assisted Suicide .................................................................................................. 8  
    Physician Assisted Suicide .............................................................................. 8  
    Euthanasia ........................................................................................................... 8  
    Palliative Sedation Therapy (PST) ...................................................................... 8  
  Standard of Care .................................................................................................. 9  
  Recommendation 1: ............................................................................................. 10  
  Determine Symptoms are Refractory ................................................................. 10  
  Recommendation 2: ............................................................................................. 11  
  Determine criteria for implementing PST are met ............................................. 11  
  Recommendation 3: ............................................................................................. 12  
  Guide for Decision Making ................................................................................... 12  
    Principles to Guide Decision-Making ................................................................. 13  
      A. Keep an open mind. The decision may be “For”, “Against”, or “Wait and See”. 13  
      B. Ensure informed consent. Actively involve the patient or the substitute decision maker. .......................................................... 14  
      C. Develop a plan. If the plan is “For PST”, consider and plan for: .................. 15  
      D. If the plan is “No PST”, or “Wait and See”, determine when this decision might be reviewed .......................................................... 15  
      E. In cases where no agreement about a plan can be reached, consider referral to the NH Ethics Committees or an independent patient advocate. ............. 15  
  Recommendation 4: ............................................................................................ 15  
  Documentation of Decision Making ................................................................... 15  
  Recommendation 5: ............................................................................................ 16
Initiating, Assessment and Care Provision ................................. 16

Once the patient is sedated: .............................................................. 16
Assessments & Care Provision ......................................................... 17

Recommendation 6: ........................................................................ 17

Supportive Care .............................................................................. 17

A. Supporting the family and friends .............................................. 17
B. Supporting the care team .......................................................... 18
C. Care after death ........................................................................ 19

Recommendation 7: ........................................................................ 19

Pharmacological Interventions – Initiating and Maintaining PST .............. 19

Anxiolytic Sedatives .......................................................................... 20
Neuroleptics .................................................................................. 22
Sedative Antiepileptics ................................................................. 23
General Antiepileptics .................................................................. 24
Palliative Sedation Treatment Dosing ............................................. 25
Drugs NOT RECOMMENDED for Palliative Sedation Therapy .......... 25

References ...................................................................................... 27

Appendix A: Selection and Duties of the Substitute Decision Maker(80) ....... 35

Duties of Representatives: ............................................................... 36
Duties of Temporary Substitute Decision Makers: ........................... 36

Appendix B: Richmond Agitation Sedation Scale (RASS) ....................... 38

Procedure for RASS Assessment ..................................................... 38
HOW CAN PALLIATIVE CARE HELP YOU MANAGE DIFFICULT SYMPTOMS? WHAT ABOUT REFRACTORY SYMPTOMS?

Palliative care aims to relieve suffering and to help patients and families with life limiting illness live as actively as possible with good quality of life, neither hastening nor postponing death. Although many palliative patients experience symptoms, most are well managed when appropriate medications and treatments are used. The Northern Health (NH) Hospice Palliative Care (HPC) Symptom Guide and NH HPC Psychosocial Care Guide are valuable evidence based resources to help manage symptoms.

At times, symptoms prove more difficult to manage or do not respond to commonly used medications. In these cases, palliative care consultation can provide a key interdisciplinary resource. Northern health has an interdisciplinary team of palliative care consultants that are available to support care providers. The contact list can be found on the NH iportal site.

The NEW HPC Symptom Guide ‘Refractory Symptoms and Palliative Sedation Therapy’ will help health care teams determine when a symptom is refractory versus difficult to manage. Refractory symptoms are those where “all possible treatments have failed, or it has been determined that there is no method within the time frame and risk: benefit ratio the patient can tolerate.” (Levy & Cohen, 2005) Consultation is strongly recommended to determine if a physical symptom is refractory. Consultation MUST be sought when the refractory symptom is ‘existential’ e.g. non-physical suffering.

The guideline provides criteria and direction for when the extraordinary intervention of Palliative Sedation Therapy (PST) is an appropriate therapy. PST may only be considered for a patient with terminal illness in the last days of life experiencing refractory symptoms. Although sedative medications and brief periods of sedation may be the unintended but predictable adverse effect of medication used in aggressive symptom management, this is different than PST. PST aims to relieve intolerable suffering from refractory symptoms by the intentional lowering of a patient’s level of consciousness in the last days of life by the proportional and monitored use of non-opioid sedative medications. Opioids alone do not provide adequate sedation and should never used for that purpose. Pharmacological treatment choices appropriate for PST are outlined in detail in the guide including anti-anxiolytics, neuroleptics, and sedative anti-epileptics.

Users are guided through a process of informed consent with active involvement of the patient and substitute decision maker(s) and interdisciplinary health team. Recommendations for discussions, documentation, and patient and family support are included. Guide for initiating and adjusting sedation proportional for symptom relief are outlined.

PST is an extraordinary intervention requiring expertise in clinical care, communication and interdisciplinary team process. When used appropriately, the patient experiences symptom relief until death occurs through the natural course of the underlying disease, usually within hours to days. (deGraff & Dean, 2007)

NH-HPC Consultation team is available for support and guidance. If palliative sedation therapy is being considered it requires review of this Guide as well as the Decision Support Tools available on the palliative care iportal page.

If palliative sedation therapy is initiated in Northern Health, please follow the link to access a tool intended to obtain your feedback and assess the utility of the guide. Feedback is welcomed from any member of the patient care team using the Palliative Sedation Clinician Feedback Form 10-513-7012.
REFRACTORY SYMPTOMS AND PALLIATIVE SEDATION THERAPY

RATIONALE

The NH Refractory Symptom and Palliative Sedation Therapy Guide has been adapted from the FH Refractory Symptom and Palliative Sedation Therapy Guide 2011 which underwent an extensive external and internal review process including appropriate interdisciplinary, ethics, legal, and practice council committees within Fraser Health.

The NH Refractory Symptom and Palliative Sedation Therapy Guide is available as a resource for generalist inter-professional primary care providers working in various settings in Northern Health, British Columbia. This Guide has been approved by the NH HPC Consultation team as a best practice resource.

SCOPE

This guideline provides recommendations for the ongoing assessment and symptom management of adult patients (age 19 years and older) living with advanced life threatening illness and experiencing refractory symptoms in the last days of life. For the management of a specific symptom, see Northern Health Hospice Palliative Care Symptom Guide on the relevant symptom.

This guideline does not include or suggest any support for practice of physician assisted suicide (PAS) or euthanasia. It does not cover emergency sedation for crises such as exsanguinations and respiratory crisis in the last minutes of life.

BACKGROUND

Palliative care aims to relieve suffering and to help patients live as actively as possible, neither hastening nor postponing death. NH HPC Symptom Guide are valuable evidence based resources for managing symptoms. Although many patients with life threatening illness experience symptoms, most are well managed when appropriate medications and treatment approaches are used.

When symptoms are difficult to manage, NH-HPC consultation provides a key interdisciplinary resource for providers, patients & families.

In rare circumstances, thorough interdisciplinary assessment and treatment of a palliative patient’s symptoms may not result in sufficient relief. When all possible treatments have failed, or no methods are available for palliation within an acceptable time frame, the symptom is determined to be refractory.

The incidence and type of refractory symptoms vary significantly according to patient demographics, regional access to adequate pain management and palliative care, and the availability of interventions, health care professional treatment patterns and the standards of care. The most common refractory symptoms are: delirium, dyspnea, pain, nausea and vomiting.

(1,2) The most common refractory symptoms are: delirium, dyspnea, pain, nausea and vomiting.
It is strongly recommended that a HPC consultation is sought to determine that a
physical symptom is refractory, to assist decision making, and to support
managing sedation therapy. Consultation must be sought when the refractory
symptom is thought to be existential suffering.

Palliative Sedation Therapy (PST) is an infrequent and extraordinary intervention
that requires inter-professional expertise and effective communication skills of the
caregivers involved. (5, 6)

DEFINITION OF TERMS

Palliative Care is defined by the World Health Organization as “an approach that
improves the quality of life of patients and their families facing the problems
associated with life-threatening illness, through the prevention and relief of
suffering by means of early identification and impeccable assessment and
treatment of pain and other problems, physical, psychosocial and spiritual.

Palliative care:

• provides relief from pain and other distressing symptoms;
• affirms life and regards dying as a normal process;
• intends neither to hasten or postpone death;
• integrates the psychological and spiritual aspects of patient care;
• offers a support system to help patients live as actively as possible until
death;
• offers a support system to help the family cope during the patient’s
illness and in their own bereavement;
• uses a team approach to address the needs of patients and their
families, including bereavement counselling, if indicated;
• will enhance quality of life, and may also positively influence the course
of illness;
• is applicable early in the course of illness, in conjunction with other
therapies that are intended to prolong life, such as chemotherapy or
radiation therapy, and includes those investigations needed to better
understand and manage distressing clinical complications.” (20)

Refractory Symptoms (also “Intractable”, “Unbearable”) are physical and
emotional symptoms for which “all possible treatments have failed, or it is
determined that any methods that are available would not work within a
reasonable time frame, would cause undue suffering for the patient, or would
cause intolerable or unacceptable side-effects.” Often geography and the
relative availability of interventions influence the determination of refractoriness.
(2, 1)
Difficult Symptoms, by contrast could possibly respond within a tolerable time frame, to aggressive interventions that yield adequate relief and preserve consciousness, without excessive adverse results. 

Suffering (also “Distress”, “Anguish”) is “a sense of helplessness or loss in the face of a seemingly relentless and unendurable threat to quality of life or integrity of self”. Although pain, dyspnea, delirium, nausea and vomiting are frequent causes of suffering at the end of life, hopelessness, remorse, anxiety, loneliness, and loss of meaning also cause suffering. Suffering involves the whole person in physical, psychological, and spiritual ways and can also affect family, friends, and caregivers.

Existential Suffering (also “Psychic” or “Spiritual” Suffering, Distress or Anguish) describes the experience of patients facing terminal illness who may or may not have physical symptoms but report distress that is related to “the meaninglessness in present life”, hopelessness, being a burden on others, feeling emotionally irrelevant, dependant, isolated or grieving, that is unrelated to a psychiatric disorder or social isolation. Existential distress specifically develops as a result of facing one’s own mortality.

Moral Distress occurs as an “emotional and spiritual response when an individual is obligated to act in a manner which breaches their personal belief and value system” and/or "arises when one knows the right thing to do, but institutional constraints make it nearly impossible to pursue the right course of action.”

Natural Sedation or drowsiness occurs as part of the dying process. Progressive drowsiness or sedation is expected and occurs as part of reduced consciousness leading through coma to death. This is due to a combination of renal/hepatic/septic/neurologic processes resulting in body shutdown.

Consequential (ordinary/mild) Sedation is the unintended but predictable adverse effect of some drugs used for symptom control in patients who are not actively dying. This type of sedation may be transient and is often reduced or eliminated with dose adjustment, or as tolerance develops. Brief periods of sedation may be used in the general management of pain, dyspnea or delirium. This is not PST.

Respite Sedation (intermittent) is intended to be temporary. The patient is sedated, then awakened after an agreed upon period (usually 24-48 hours) to assess whether or not the symptom remains refractory. “The practice of respite sedation recognizes that either a symptom might respond to continued or future therapy or that the patient’s ability to tolerate the symptom may be improved following the rest and stress reduction provided by sedation.”

Family is a term that is used to describe those who are closest to a patient. It is not exclusive to those who are related by blood or by marriage. It is a term used
to describe someone that a patient considers to be “like” a family member, regardless of blood relations. (31)

**Assisted Suicide** is the act of intentionally killing oneself with the assistance of another who provides the knowledge, means, or both. In **Physician Assisted Suicide**, the other person is a physician. (32)

**Physician Assisted Suicide** means knowingly and intentionally providing a person with the knowledge or means or both required to commit suicide, including counselling about lethal doses of drugs, prescribing such lethal doses or supplying the drugs. (32)

**Euthanasia** means knowingly and intentionally performing an act that is explicitly intended to end another person's life and that includes the following elements: the subject has an incurable illness; the agent knows about the person's condition, AND commits the act with the primary intention of ending the life of that person. (32)

**Palliative Sedation Therapy (PST)** (also “Terminal Sedation”, “Controlled Sedation”, “Total Sedation”, “Deep Sedation”, “Continuous Sedation”) is the intentional lowering of a patient’s level of consciousness in the last days of life. It involves the proportional and monitored “use of sedative medications to relieve intolerable suffering from refractory symptoms by a reduction in patient consciousness”. (5) The patient experiences symptom relief until death occurs by the natural course of the underlying disease, usually within hours to days. (5) Decision-making is focused on relieving the patient’s suffering and creating a more tolerable situation by adjusting the combination and doses of drugs administered.

PST can also be regarded as inducing and maintaining "sleep" in very specific circumstances:

- for the relief of refractory suffering, when all other possible interventions have failed, and
- when the underlying disease is irreversible and death is expected in hours to several days. (3,4,5,8,12,24, 33-38)

In clinical practice, PST usually does not alter the timing or mechanism of a patient’s death, as refractory symptoms are most often associated with very advanced terminal illness. (37-45)

In using Palliative Sedation Therapy (PST) the intention is symptom relief by proportional use of sedative medications to lower consciousness only as much as is necessary to obtain symptom relief. In euthanasia or physician assisted suicide (PAS), there is no proportional use of medications as the primary intent is the death of the patient. (46)
STANDARD OF CARE

1. Determine symptoms are Refractory
2. Determine criteria for implementing PST are met
4. Documentation of Decision-Making
5. Initiating, Assessment and Care Provision
6. Supportive Care
   a. Supporting the Family and Friends
   b. Supporting the Care Team
   c. Care after Death
7. Pharmacological Interventions - Initiating and Maintaining PST
RECOMMENDATION 1: DETERMINE SYMPTOMS ARE REFRACTORY

A symptom or symptoms are considered refractory when “all possible treatment has failed, or it is estimated that no methods are available for palliation within a time frame and risk-benefit ratio that the patient can tolerate”\(^{(3)}\).

In considering the use of Palliative Sedation, the attending physician should ensure that the patient is assessed thoroughly to identify and treat reversible problems. The following points should be viewed:

- Non-pharmacological approaches, such as distraction and relaxation techniques, have been maximized
- All other pharmacological treatments, such as appropriate titration of opioids, have been maximized.

The patient must be the one suffering from refractory symptoms. It is not uncommon for families to request PST on behalf of their loved one, citing a perception of suffering, when in fact it is the family that is suffering.\(^{(47)}\)

In order to ensure that thorough assessment of and intervention for one or more difficult symptoms has been attempted, the reader is referred to the relevant symptom section in the NH Hospice Palliative Care Symptom Guide. To determine if the criteria are met for a refractory symptom, consider the following questions regarding possible interventions, time frame and tolerability.\(^{(3, 8, 16, 18, 22, 28, 59)}\)

- Are further interventions capable of providing adequate relief?
- Are interventions likely to provide relief within a tolerable time frame?
- Will the intervention itself increase physical or emotional suffering?

A useful framework for assessing whether or not PST should be considered is the Latimer Ethical Decision Making Model.\(^{(5, 7-9, 11-13, 14, 16, 19, 28-30, 60-61)}\)

- Patient’s Illness - extent of disease, prognosis, and nearness to death
- Patient’s Experience - symptom intensity, impact on quality of life, suffering, demoralization, and lack of dignity
- Patient as a Person - goals, hopes, and plans in light of current symptom, and wishes as contained in an advance care plan (if one has been completed)

Explore other options and supports for the patient and family. Meaning based interventions, dignity conserving therapy and other spiritually based approaches have been useful to help patients and families find meaning in the dying process.\(^{(62-73)}\) See NH HPC Psychosocial Care Guide.

The treating physician should also assess the patient for any conditions which may benefit from psychiatric consultation.\(^{(5, 22, 74)}\)
It is important not to label difficult symptoms as refractory because of a lack of skill or knowledge on the part of the health care provider, or because of an unwillingness to request a consultation. **Consultation is strongly recommended in cases of refractory symptoms to ensure that all possible options have been explored.** Such consultation may be with a:

- member of the [NH HPC Consultation Team](5,7-9,11-13, 14, 16, 19, 28-31,33), even if this can only be done via telephone.
- physician may also consult the Provincial Physician Palliative Hot Line by calling:
  - 1-877-711-5757 (24/7 telephone service)
  - physician colleague that is more experienced in palliative care

### RECOMMENDATION 2: DETERMINE CRITERIA FOR IMPLEMENTING PST ARE MET

Health care professionals providing end of life care have a responsibility to offer sedatives in appropriate circumstances, usually targeted at specific symptoms (ordinary sedation). Palliative Sedation Therapy (PST) is occasionally necessary to relieve otherwise refractory symptoms, with the degree of sedation proportional to the severity of the target symptom. PST is an extraordinary intervention, but can be viewed as part of the continuum of palliative care. (47, 59, 75-77)

PST should only be considered in the rare circumstance that thorough interdisciplinary assessment and treatment of a patient’s refractory symptoms has not resulted in sufficient relief (or is associated with unacceptable side effects), and when sedation is needed to meet the patient’s goal of relief from refractory symptoms. (3, 8, 16, 18, 22, 28, 59, 65, 74)

In cases of refractory symptoms, ethical principles and legal rulings support the use of palliative sedation therapy to relieve otherwise refractory symptoms. (46, 78) In Canada, the enactment of the Criminal Code is under federal jurisdiction, but the administration of justice is a provincial responsibility. The Attorney General of each province has discretion as to whether charges are laid. In accordance with these responsibilities, in November 1993, the British Columbia Ministry of the Attorney General issued guidelines for Crown Counsel (Policy 11-3-93, File no. 56880-01 Eut 1). (46) According to these guidelines, palliative care and withholding or withdrawing medical treatment will not be subjected to criminal prosecution when provided or administered according to accepted ethical medical standards.

The factors considered by Crown Counsel as to whether the acts of a qualified medical practitioner, or a person acting under the general
Refractory Symptoms and Palliative Sedation Therapy Guide

supervision of a qualified medical practitioner, constitute “palliative care” include:

• Whether the patient was terminally ill and near death with no hope of recovery
• Whether the patient’s condition was associated with severe and unrelenting suffering
• Whether accepted ethical medical practices were followed, and
• Whether the patient was participating in a palliative program or palliative care treatment plan.

Criteria for implementing PST are as follows: (5, 6, 33)

• The patient is terminally ill and near death with no hope of recovery
• In all but the most unusual circumstances, death is anticipated within hours to days (8, 17, 18, 24, 28, 33-34, 77, 79)
• A “Do Not Resuscitate” order is in effect
• The patient is in a palliative program or has a palliative care treatment plan
• The patient has refractory symptoms
• The clinician’s intent is to relieve refractory symptoms
• The planned degree of sedation is proportionate to the severity of refractory symptoms
• The patient is fully informed and involved in the decision making. When the patient is not able to participate, consent needs to be provided by the patient’s substitute decision maker or legal representative who is acting in accordance with the patient’s values and beliefs. See Recommendation 3 B for further discussion of consent. Refer to Appendix A for process of selection and duties of temporary decision makers.

Management of existential suffering is controversial. Requests for sedation because of existential suffering are the most challenging and difficult to address. (2, 9, 30, 48-58)

PST for the management of refractory existential suffering should never be undertaken without consultation. Such consultation may be obtained from a member of an interdisciplinary hospice palliative team with knowledge and understanding of the patient’s belief system. This may be a hospice-palliative physician or a psychiatrist/clinical psychologist, in addition to a social worker, a medical ethicist, or a spiritual care practitioner.

RECOMMENDATION 3: GUIDE FOR DECISION MAKING
The question of providing palliative sedation therapy may be raised by the patient or family/loved ones, either explicitly or indirectly, in the form of a request to relieve suffering. However, in deciding whether or not to initiate PST (or another plan of care that can still address the refractory symptoms of the patient), a formal discussion should take place. Most often, this is a family meeting with all relevant family/loved ones and health care professionals present to review the patient’s condition and explore options.

PRINCIPLES TO GUIDE DECISION-MAKING

A. Keep an open mind. The decision may be “For”, “Against”, or “Wait and See”.

Use a systematic and inclusive process for determining whether to use sedation for refractory symptoms and how sedation is to be used, such as this process outlined by deGraeff and Dean. (5)

1. Actively involve the patient and ideally substitute decision maker(s) (SDM)
   - Elicit patient’s values, beliefs and goals
   - Determine preferences for information and involvement in the decision
   - If unable to participate, refer to previous discussions or advance care planning documentation
   - Discuss with patient and family that there is no chance of recovery and life expectancy is very limited
   - Discuss the therapeutic options, including potential benefits and risks
   - Make clear the intent of PST is comfort and symptom management, not hastening death
   - Facilitate patient-family discussion
   - If necessary, remind the substitute decision maker of the duty to uphold the patient’s wishes, or to express what is known about the patient’s previously expressed preferences
   - Provide support to family members finding it difficult to make critical decisions for a loved one

2. Involve all members of the team providing care for the patient. Those who should be present include:
   - The patient and ideally the SDM(s) - give the patient an opportunity to specify who s/he would like to be present at the meeting, and don’t make assumptions about who should or shouldn’t be there;
   - The physician who will be documenting the meeting and writing the orders;
• A nursing team member with knowledge of the patient’s condition and care needs;
• A psychosocial practitioner with knowledge of the patient and/or experience in palliative care or end-of-life decision-making, such as a palliative social worker, spiritual care practitioner, clinical psychologist, or medical ethicist;
• A clinical pharmacist with knowledge of the patient, and/or experience in palliative care, especially in medically complex situations.
  o Agree on the goals of care and proportionality of PST
  o Elicit practical and ethical/moral concerns of the team about the use of PST in this case
  o Tailor the specific sedating interventions to the patient’s values and clinical goal of care

3. Whenever possible, consider the needs of all those involved in choosing the time for initiating sedation.

B. Ensure informed consent. Actively involve the patient or the substitute decision maker.

As with all treatment, the use of PST requires informed consent. Under Provincial law, in deciding whether an adult is incapable of making a particular health care decision, the decision must be based on whether the adult demonstrates that he or she:

1. understands the information being given about his or her health conditions;
2. understands the nature of the proposed health care, including the risks, benefits and alternatives and
3. understands as well that the information applies to his or her situation

If a patient is not able to understand the above, then a substitute decision maker needs to be identified. The treating physician or other Health Care professional should first determine whether there are any formally appointed substitute decision makers (Committee of Personal/Personal Guardian or Representative; as well as if advance care planning conversations or documents (including an Advance Directive) have been made or discussed. Copies of documents should be provided and reviewed by the health care team. Previously expressed wishes or instructions of the adult patient must be followed and carried out through consent by the substitute decision maker(s) (SDM), unless they are appointed as Committee of Personal/Personal Guardian. If such documents are not in place or information available is not sufficient/applicable, in British Columbia, the requirements for temporary substitute decision making are set out in The Health Care (Consent) and Care Facility (Admission) Act. See Appendix A for further information about selecting the SDM and his or her duties. Contact a social work department to consult with the Office of the Public Guardian (PGT) if no one is
available to act as SDM or there is conflict about who should be the SDM. The PGT can appoint someone or act as SDM.

The care team should confirm that the patient’s decision is not being affected by psychological or social pressure. (12)

C. Develop a plan. If the plan is “For PST”, consider and plan for:

- timing the initiation of sedation, consider the physical, emotional and physical needs of patient and family
- sedation to be proportional to the symptom distress/requirement for symptom relief
- whether to provide artificial hydration
- need for Foley catheter, continued bowel care
- concurrent medications for control of other symptoms
- how to support family and staff if the patient does not die within the expected time frame
- whether the sedation therapy will be discontinued or reversed after a period of time

D. If the plan is “No PST”, or “Wait and See”, determine when this decision might be reviewed.

E. In cases where no agreement about a plan can be reached, consider referral to the NH Ethics Committees or an independent patient advocate.

**RECOMMENDATION 4: DOCUMENTATION OF DECISION MAKING**

Careful documentation of the team/family meeting, who was present, and the decision made is essential. It could be done by any member of the team, such as the physician, social worker, nurse, or other allied health professional and should be made in the permanent patient record.

**The attending physician as a minimum, must document in the permanent record:**

- A DNR / No CPR order and signed document is in place. (17-18, 33)
- The criteria and rationale used to determine that the symptom is refractory. (17-18, 33)
- The consultation process between the attending physician, palliative care consultants, patient and family.
- A summary of the discussion(s):
  - The people involved in the decision making.
  - The information provided.
  - The decision reached.
Record the patient’s expressed wishes, in his or her own words, as much as possible, or refer to prior documented conversations between the patient and other healthcare worker(s).

Informed consent for PST has been given by the patient, substitute decision maker, or legal representative.

- A summary of the plan:
  - If NO sedation is desired, document the agreed upon care plan. Is there a plan for further discussions? Are further consultations to be requested? Is an ethical review required?
  - Document the plan in relation to:
    - Timing of initiation.
    - Medical orders for sedation and for concurrent therapies, as needed.
    - Hydration/Nutrition.
    - Plan for managing foreseeable events
    - Anticipate possible crises, and how they will be managed

**RECOMMENDATION 5: INITIATING, ASSESSMENT AND CARE PROVISION**

Initiating palliative sedation may be an emotionally charged time, not only for the patient and family but also for health care providers. This is particularly true in situations in which the level of consciousness is rapidly lowered, rendering it difficult or impossible to communicate with the patient. It is beneficial to have the family and/or loved ones integrated into the plan of care as much as possible. Inform them of what to expect, reassure about expected changes in their loved one’s condition, what practical things they can do while their loved one is sedated, and provide opportunities to express their emotions.

**ONCE THE PATIENT IS SEDATED:**

- Ensure frequent communication with the family for reassurance, support, feedback, and ongoing decision-making.
- Ensure support is in place for patient and family, including palliative services, social work and spiritual care as available and desired by the patient or family. For communities without local support in this regard, please consider regional resources i.e. regional cancer care social worker. Through presence, intent, words, and touch, convey compassion for the patient and family.
- Assume the patient can hear, and encourage visitors to talk or read to the patient, or play his or her favorite music if appropriate.
- Provide meticulous physical care because the patient will have reduced movement
• (e.g. loss of ability to blink, and other protective reflexes). (22)
• Encourage family to continue to touch their loved one.
• Discuss with family if they wish to participate in providing care. If desired, show them how to provide mouth care, eye care, hand or foot massage, or skin care as appropriate. If desired, include the family in repositioning the patient.
• Monitor for symptom relief.
• Assess for bladder emptying and place a urinary catheter when needed. Continue with appropriate bowel care. (22)

ASSESSMENTS & CARE PROVISION

The patient should be monitored on a regular basis to be sure that the goal of relief of refractory symptoms is being met.

After PST has been initiated, the following care should be provided and documented in the permanent record by the team members who are caring for the patient regularly throughout the shift:

• Response to PST - signs of symptom relief, Richmond Agitation Sedation Scale (RASS) See Appendix B or RASS Form 10-513-5008 (121)
• Assessment of the balance between symptom relief and level of sedation, along with appropriate drug and/or dosage changes
• Assessment of physical care needs and provision of care – skin care, mouth care, repositioning, bowel care, other care as needed
• Family coping and interventions to support the family
• Indicators for need to re-assess continuation of PST
• Outcome and care after death

Note: Respiratory rate and oxygen saturation should only be considered in exceptional cases. It is important to note that changes in respiratory rates and patterns, as well as reduction in oxygen saturation are normal end of life changes and will occur whether or not the patient is receiving PST. To titrate PST according to these parameters would therefore be inappropriate when death is imminent.

RECOMMENDATION 6: SUPPORTIVE CARE

A. SUPPORTING THE FAMILY AND FRIENDS

Palliative care includes comforting and supporting the patient’s family and friends, who play an important role both when palliative sedation is being considered and while it is being carried out. They often serve as caregivers, observers, informants and representatives in addition to their role as partner, child, relative or friend. They each pass through their own emotional / spiritual journey which may include feelings of doubt, guilt, fear, sorrow, and mourning. They may also
feel relief that the suffering of their loved one has come to an end. Information, explanation, cooperation and ongoing evaluation of the situation are essential if the palliative sedation is to work to good advantage and those involved can bid a meaningful farewell. The health care team should communicate with the patient’s family using language they can understand.(15)

Family members can be an important source of information about the well-being of the patient. It is helpful to meet with them at set times for periodic updates or to discuss new circumstances that may arise. It also allows the health care providers to watch for signs of stress or burn-out in the family, and encourage them to care for themselves with adequate rest and nutrition.(25)

Ascertain the level of involvement that the family wants in the process. Provide an opportunity for the patient, if possible, to express what s/he may want from their loved ones, or would find comforting, during the time they are sedated. Obtain information on anything that the patient would want or need before sedation is initiated, i.e., rituals, spiritual or religious rites, saying goodbyes or expressing their feelings to family or team members. Conversely, is there anything that a family member or loved one needs to say to the patient prior to the initiation of PST?

B. SUPPORTING THE CARE TEAM

In cases where PST is being initiated, a profound empathy for the patient’s suffering is common. To bear witness and still be professionally present and supportive for a patient and family can be an emotionally exhausting experience. Therefore, it is helpful that the team members caring for a patient and family discussing and possibly initiating PST be offered opportunities to discuss their own personal feelings. This may include formal or informal debriefings before or during the initiation of PST or after the death of the patient or individual meetings with team members. (4, 15, 51, 59)

A more organized debriefing session for involved team members may be considered whenever:

- Management of refractory symptoms was especially challenging.
- The decision to initiate PST was difficult.
- Death was unusually arduous.
- Significant complications arose.
- Death occurred during intended respite sedation.

The debriefing session(s) should be facilitated by an experienced social worker, clinical counsellor, psychologist or spiritual care practitioner, who may or may not have been involved in the care of the patient. Most importantly, such offering of support can positively impact or offset any moral distress experienced by health care providers. It also serves as an opportunity for increased team cohesion, overall team functioning, and learning opportunities for what was done well or could have been done differently. Northern Health offers an Employee and Family Assistance Program (EFAP) that can be accessed for counselling support for any
type of personal, family, or work-related concerns including but not limited to anxiety, stress, conflict, trauma, grief and loss.

C. CARE AFTER DEATH

A patient receiving PST will eventually show some or all of the indicators of impending death (mottling and cooling of the periphery, irregular and/or noisy respirations) and death will occur as a natural outcome of the underlying disease within hours or days.\(^{(118)}\) Palliative Sedation Therapy has not been shown to hasten death: there is no difference between the length of stay of those patients who receive palliative sedation and those who do not.\(^{(39,40,43,45,119)}\) Death can occur sooner or later than the family or team had expected, although more than 85% of patients receiving PST die within 3 days and 98% do so within 7 days.

The family may need advice about burial, cremation, financial arrangements etc. They may have cultural beliefs about who may touch or wash the body, and how it is to be laid out. During this time, they should be given a chance to express their feelings about the way the patient died. Some families might appreciate the opportunity to debrief with the care team following the patient’s death. This can encourage expression of their emotions and their feelings about the role they played and the support they received from others and the professionals involved in the case.\(^{(15)}\) The family may find it particularly helpful to have the attending physician present during such a session.

Family and friends should be asked whether they would like to receive information about bereavement support. Bereavement support and follow up is available through local hospice societies or other community resources, and on various websites.

<table>
<thead>
<tr>
<th>RECOMMENDATION 7:</th>
<th>PHARMACOLOGICAL INTERVENTIONS – INITIATING AND MAINTAINING PST</th>
</tr>
</thead>
</table>

The patient’s care location (home, hospice residence, acute medical unit, tertiary palliative unit, critical care unit) and the availability of medication administration routes, such as intravenous, primarily guide the PST medication used. The goal of pharmacological treatment is proportional reduction of consciousness to a level sufficient to relieve symptoms.

If a patient is already being treated with opioids and/or antipsychotics, these medications should be continued during sedation in accordance with the patient’s needs. When an existing medication is being administered continuously via the parenteral route, it is preferable to administer the sedative drugs via a separate site. This avoids an undesirable increase in the existing medication when the doses of sedatives are increased, and avoids potential drug incompatibilities when mixed together.
There is no strong evidence to support a ranking of medications. Choices depend on the experience of the physician, drug availability, institutional policy, and location.

**ANXIOLYTIC SEDATIVES**

The most common initial choice of PST medication in the literature is a benzodiazepine, such as midazolam or lorazepam. They provide a high potential for sedation, a low risk of respiratory depression at sedative doses, and a wide safety margin. Where feasible, the use of midazolam by continuous subcutaneous infusion (CSCI) is preferred, to permit responsive titration. In general, subcutaneous administration is preferable to intravenous administration because of the practical advantages of subcutaneous infusion and the greater risk of apnea when bolus injections are administered intravenously. Where continuous infusions are not possible, consider using longer acting lorazepam by intermittent injection or sublingual administration. In general, midazolam is preferred over lorazepam because of its more immediate titration responsiveness, although lorazepam SL or buccally might be the simplest method in the home.

When the patient has delirium, benzodiazepines are not recommended as sole agents for PST, and should be combined with a neuroleptic (5, 81-82) or phenobarbital.

### MIDAZOLAM

| Midazolam Initiation | 1 to 5 mg subcut or IV q 5 minutes until settled.  
In emergencies, when a very rapid lowering of consciousness is required, bolus injections can be given more frequently. In other situations, a quiet atmosphere and gradual changes in consciousness are more important than speed. |
|----------------------|--------------------------------------------------------------------------------------------------|
| Midazolam Maintenance | Follow bolus initiation dosing with 1 mg per hour CSCI or continuous IV infusion (CIVI)\(^\text{[105]}\) and titrate every 15 minutes until adequately sedated.  
For elderly patients with a low body weight, no previous treatment with benzodiazepines, and no urgent need for rapid sedation, a low initial dose of 0.5 mg per hour is preferable.  
Usual dose is 30 to 100 mg per day, yet range is broad from 3 to 1200 mg per day.\(^\text{[81]}\) |
| Midazolam Titration | Individualized titration of midazolam is required.  
Provide p.r.n. intermittent doses q1h p.r.n. equal to the hourly maintenance infusion rate.  
Adjust the maintenance dose every 1 to 2 hours.\(^\text{[105]}\) based on number of p.r.n. boluses needed. If sedation is insufficient, the dose of midazolam can be doubled every 1 to 2 hours in combination with a bolus until an adequate effect has been achieved.  
At dosages greater than 20 mg/hour (480 mg/day) consider adding, or switching to, second line treatment.\(^\text{[105]}\) |
| Dosing Special Populations | Use lower initial doses in patients with no previous treatment with benzodiazepines, cachexia, age over 60 years, renal, hepatic or cardiac |
impairment, and concomitant opioid administration.

- Higher doses may be needed in patients with significant previous benzodiazepine exposure, patients requiring a long duration of sedation, or in young patients.\(^{(83)}\)

<table>
<thead>
<tr>
<th>Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Tolerance may develop to the sedative effects of midazolam, sometimes to the point where the patient may unexpectedly recover consciousness. The dosage of midazolam may have to be increased over time, watching for this tolerance effect, mainly in younger patients.(^{(6)})</td>
</tr>
<tr>
<td>• Delirium is a rare complication (seen especially in elderly) on the initiation of sedation, and if occurs, it is advisable to increase the dosage rapidly.</td>
</tr>
<tr>
<td>• Paradoxical excitation reactions to midazolam, including hyperactive or aggressive behavior, have been reported (2% incidence). There have been some reports of successfully reversing paradoxical excitation with flumazenil, haloperidol, and ketamine; however, these reports have not involved PST. (^{(84-89)}) <strong>As the goal of PST is to sedate to symptom relief, flumazenil would not be the best choice.</strong> If paradoxical sedation occurs stop the midazolam to prevent further episodes and sedate with an alternate drug.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Infusion Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Compatible in solutions of normal saline, D5W or Lactated Ringers. (^{(35-37)})</td>
</tr>
<tr>
<td>• Compatible with morphine and hydromorphone in the same syringe or minibag, (^{(84)}) but does not allow for individual titration of medications.</td>
</tr>
</tbody>
</table>

**LORAZEPAM**

<table>
<thead>
<tr>
<th>Lorazepam Initiation</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 0.5 to 1 mg subcut or IV q 15 minutes.</td>
</tr>
<tr>
<td>• Alternatively: start with 1 to 4 mg sublingually or buccally.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lorazepam Maintenance</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Continue with 1 to 4 mg subcut or IV q 2 to 4h regularly or 1 to 8 mg sublingually or buccally. Usual dose is 4 to 40 mg per day.(^{(74)})</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lorazepam Titration</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Titrate with intermittent doses of 0.5 to 2 mg q 2h p.r.n.(^{(74)})</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dosing Special Populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Lorazepam pharmacokinetics remain unaltered with age,(^{(90)}) but elderly may be more sensitive.(^{(91)})</td>
</tr>
<tr>
<td>• Renal impairment may require dosage adjustment, guidelines unavailable.(^{(90)})</td>
</tr>
<tr>
<td>• Liver impairment – no dosage adjustment generally necessary.(^{(90)}) Pharmacokinetics altered less in hepatic dysfunction versus most other benzodiazepines.(^{(90)}) Cirrhotic patients may require lower dosing.(^{(91)}) Obese patients may need greater doses.(^{(91)})</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Volume becomes a problem if used subcut at higher doses.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Infusion Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>• NS, D5W preferred(^{(90)}) but compatibility is concentration dependent, time limited and temperature sensitive.(^{(90-92)})</td>
</tr>
<tr>
<td>• Lorazepam is best avoided for infusion due to risk of precipitation.</td>
</tr>
</tbody>
</table>

Midazolam is the most commonly used drug for palliative sedation\(^{(83)}\) yet if it, or lorazepam, is inadequate to provide the desired effect, consider proceeding to, or adding, the following alternatives.
NEUROLEPTICS

Methotrimeprazine is a useful second-line choice for PST. It acts on multiple receptors and has some antiemetic and analgesia effects.\(^{(113)}\) It provides significant sedation, can be administered intravenously, subcutaneously, continuously or intermittently. It can be used in combination with midazolam. Other neuroleptics have been used for PST, but experience with them is much more limited. Haloperidol does not provide the degree of sedation necessary for PST; however, it remains useful as an adjuvant treatment for nausea and vomiting.

<table>
<thead>
<tr>
<th>METHOTRIMEPRAZINE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methotrimeprazine Initiation</strong></td>
</tr>
<tr>
<td>- 10 to 25 mg subcut or IV q 15 to 30 minutes until settled.</td>
</tr>
<tr>
<td>- No dilution necessary for subcut intermittent administration; however for IV intermittent doses or continuous infusion consult parenteral manual for dilution instructions.(^{(96)})</td>
</tr>
<tr>
<td><strong>Methotrimeprazine Maintenance</strong></td>
</tr>
<tr>
<td>- 10 to 50 mg subcut q 4h or 0.5 to 8 mg per hour infusion subcut or IV.(^{(105)})</td>
</tr>
<tr>
<td>- Dose range is 25 to 250 mg per day.(^{(81,95)})</td>
</tr>
<tr>
<td><strong>Methotrimeprazine Titration</strong></td>
</tr>
<tr>
<td>- Use p.r.n. doses up to q 1h p.r.n.(^{(114)}) Once settled, adjust regular doses every 8 hours until stable. May accumulate due to its long half-life, dosage reduction may be needed, especially after a few days.(^{(15)})</td>
</tr>
</tbody>
</table>

**Dosing Special Populations**
- Coadministration in patients on opioids or phenobarbital may need dose reduction by one-half.\(^{(93,96)}\)
- Subcut administration reported to be twice as potent as oral.\(^{(93,97)}\)
- Prostatic hypertrophy patients may be more sensitive to anticholinergic effects.
- Phenothiazines can lower seizure threshold, avoid in patients in whom cerebral irritation is a potential problem.\(^{(99)}\)
- Hepatic and renal impairment – use with caution, no specific dosing available.

**Precautions**
- Extrapyramidal side effects may appear with high doses of any neuroleptic and may limit the dose of methotrimeprazine.\(^{(107)}\)
- Used alone, a neuroleptic can reduce the seizure threshold or induce myoclonus in severely ill patients.
- May cause skin irritation and require site rotation based on patient tolerance. Rotation at least every 72 hours suggested.\(^{(84)}\)

**Infusion Solution**
- D5W 93,94,96 NS has also been used.\(^{(94,96)}\)
- IV: Maximum 100 mg per 250 mL.\(^{(96)}\)

Tolerance to methotrimeprazine is rare (unlike the benzodiazepines and barbiturates).\(^{(107)}\) If the benzodiazepine and methotrimeprazine have insufficient effect, stop both and start phenobarbital.
SEDATIVE ANTIPELEPTICS

Some clinicians consider phenobarbital a first-line PST medication, while others use it as a third line option that provides sedation in cases of inadequate response to anxiolytic sedatives and/or methotrimeprazine. Phenobarbital has a long duration of action with a rapid onset, reportedly faster than midazolam. It can be administered intravenously, by CSCI, or intermittent subcutaneous injection. Its antiepileptic properties may be of additional anticonvulsant value.

<table>
<thead>
<tr>
<th>PHENOBARBITAL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Phenobarbital Initiation</strong></td>
</tr>
<tr>
<td>• 1 to 10 mg per kg induction bolus subcut or IV or 100 to 200 mg subcut. <em>(99, 116)</em></td>
</tr>
<tr>
<td>• May repeat induction bolus dose every 1 to 4 hours x 2 doses to maximum of 30 mg per kg total in first 24 hours. <em>(116)</em></td>
</tr>
<tr>
<td><strong>Phenobarbital Maintenance</strong></td>
</tr>
<tr>
<td>• Use induction dose q 8h regularly or 5 to 100 mg per hour CSCI.</td>
</tr>
<tr>
<td>• Usual dose is 600 to 1600 mg per day. <em>(74)</em> Range is 200 to 2500 mg per day. <em>(81)</em></td>
</tr>
<tr>
<td><strong>Phenobarbital Titration</strong></td>
</tr>
<tr>
<td>• p.r.n. dose should be q 4 to 8h at half or the full amount of the induction dose.</td>
</tr>
<tr>
<td>• If symptoms uncontrolled after 10mg/kg Loading Dose, may repeat q 2h to max of 30 mg/kg; after loaded to 30 mg/kg, may titrate CSCI rate if symptoms uncontrolled. <em>(116)</em></td>
</tr>
<tr>
<td>• Requires individualized dosing due to considerable variability in pharmacokinetics. <em>(99)</em></td>
</tr>
<tr>
<td>• Can accumulate due to its long half-life, of 1.5 to 4.9 days. <em>(34)</em> and dosage reduction may be needed, especially after a few days.</td>
</tr>
<tr>
<td><strong>Dosing Special Populations</strong></td>
</tr>
<tr>
<td>• Adjustments may be necessary in elderly patients or those with hepatic or renal dysfunction. <em>(101)</em></td>
</tr>
<tr>
<td>• Review concurrent medications for potential drug interactions, as several exist.</td>
</tr>
<tr>
<td><strong>Precautions</strong></td>
</tr>
<tr>
<td>• Extravasation can cause skin irritation <em>(98)</em> ranging from slight to frank tissue necrosis <em>(100)</em> due to its alkaline pH <em>(9.2-10.2)</em> <em>(102)</em> However, CSCI usually well tolerated. <em>(94)</em></td>
</tr>
<tr>
<td>• Abrupt withdrawal after prolonged use may precipitate seizures. <em>(98)</em></td>
</tr>
<tr>
<td><strong>Infusion Solution</strong></td>
</tr>
<tr>
<td>• NS, D5W. May have complex mixing requirements in combination with other drugs. <em>(94, 110)</em></td>
</tr>
<tr>
<td>• Mix just prior to use, visually inspect and do not use solution if precipitate forms. <em>(101)</em></td>
</tr>
</tbody>
</table>

Generally, phenobarbital should be used in preference to propofol because it is less complicated for clinical staff to titrate and monitor. *(122)* However, if phenobarbital does not meet the goal of symptom relief, discontinue it and try another option.
**GENERAL ANTIEPILEPTICS**

Propofol is generally regarded as a fourth line PST medication, when symptom relief has not been achieved by the above medications. However in a hospital setting, where intravenous access is readily attainable and an anesthesiologist is available, it may be preferable to consider as a second line agent.\(^{105}\) It requires intravenous access, and should be administered only by a physician with experience using this drug. Administration should preferably be done under supervision of an anaesthesiologist.\(^{105}\) It provides immediate onset, rapid titratability due to an ultra-short duration of action, and possesses antiemetic activity.

### PROPOFOL

| **Propofol Initiation** | • Induction bolus dose of 0.25 to 0.5 mg per kg IV. Give over 3 to 5 minutes.\(^{112}\) May repeat q 5 to 10 minutes until settled.  
• Slow infusion techniques preferable over rapid bolus administration. |
| **Propofol Maintenance** | • Maintenance by infusion should immediately follow the induction dose.\(^{109}\) A variable rate infusion is preferable over intermittent bolus dose administration.\(^{109}\)  
• Continuous IV infusion (CIVI) at 0.25 mg per kg per hour to a maximum of 4 mg per kg per hour (4 mcg/kg/min to 67 mcg/kg/min).\(^{81}\)  
• Generally start with 0.5 mg/kg/hr (8 mcg/kg/min) for refractory nausea and vomiting or 1 mg/kg/hr (17 mcg/kg/min) for agitated delirium or intolerable distress.\(^{122}\)  
• Usual dose is 500 to 1100 mg per day. Dose range is between 400 to 9,600 mg/day.\(^{81}\)  
• Doses greater than 4 mg/kg/hr (67 mcg/kg/min) are associated with increased risk of adverse effects.\(^{121,123}\) |
| **Propofol Titration** | • May repeat boluses q 5 to 15 minutes p.r.n. and increase CIVI by 0.25 to 0.5 mg/kg/hr q 30 to 60 minutes.\(^{81,106}\) If patient is too sedated, turn off infusion for 2 to 3 minutes and restart at lower rate.\(^{122}\)  
• May require p.r.n. bolus doses before turns, dressing changes, or potentially painful procedures.\(^{106}\) |
| **Dosing Special Populations** | • May require dosage reduction of 20 to 30% in elderly, debilitated, or hypovolemic.\(^{103}\)  
• Concurrent opioids may lower BP, reduce heart rate and cardiac output.\(^{103}\)  
• Interpatient variability in dosage requirements may occur over time.\(^{103}\) Accumulation may occur with long-term use.\(^{111}\) Tolerance can develop, necessitating a dose increase, but generally not within one week.\(^{122}\) |
| **Precautions** | • Potential bradycardia, hypotension. Also apnea during induction.\(^{112}\)  
• Hypotension more likely with rapid bolus or in elderly patients or those with compromised myocardial function, intravascular volume depletion or abnormally low vascular tone (e.g. sepsis).\(^{103,109}\)  
• High incidence of injection skin reaction (18%), and immediate or delayed discomfort may occur in 90% of adults.\(^{24}\) Occurs more frequently when small veins are used. Extravasations may cause local pain, swelling, blisters and tissue damage.\(^{24}\) |
Refractory Symptoms and Palliative Sedation Therapy Guide

<table>
<thead>
<tr>
<th>Infusion Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Transient local pain during injection may be reduced by prior injection of 10 mg of IV lidocaine (preservative and epinephrine free).&lt;sup&gt;103,109,122&lt;/sup&gt;</td>
</tr>
<tr>
<td>• Propofol infusion syndrome (one or more symptoms of bradycardia, metabolic acidosis, renal failure, cardiac failure, cardiopulmonary arrest) is rare, but may occur at high doses over 4 mg/kg/hr, or in patients with refractory status epilepticus.&lt;sup&gt;104,123&lt;/sup&gt;</td>
</tr>
<tr>
<td>• Do not use subcutaneously.&lt;sup&gt;112&lt;/sup&gt;</td>
</tr>
<tr>
<td>• Shake well before use as propofol is mixed in an egg lecithin and soybean oil vehicle.</td>
</tr>
<tr>
<td>• Replenish infusion quickly when a container empties,&lt;sup&gt;108&lt;/sup&gt; as effect wears off in 10-30 min.&lt;sup&gt;122&lt;/sup&gt;</td>
</tr>
<tr>
<td>• Pain at infusion site can be minimized by using a large vein and adding a maximum of 20 mg of preservative and epinephrine free lidocaine per 200 mg propofol immediately prior to starting infusion.&lt;sup&gt;122&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

If propofol alone does not provide adequate symptom relief, supplement with midazolam by CSCI.<sup>122</sup>

**PALLIATIVE SEDATION TREATMENT DOSING**

If the patient recovers consciousness after initially being adequately sedated, it is important to check whether the indications for PST are still present.

If the patient is not appropriately sedated to the point of symptom relief, ensure that the mode of administration and the medications are in order. Ensure there is no drug extravasation, blocked or kinked lines, or equipment malfunction. Check that delivered therapy matches intended prescribed dose.

When a patient is being cared for in the home, the use of a pump for continuous subcutaneous administration may not be logistically feasible. This is particularly the case where life expectancy is extremely short (1 to 2 days). In such circumstances, intermittent administration of sedatives is an acceptable alternative. Depending on the situation, any of the following drugs can be used for this purpose:

- Midazolam: 5 to 10 mg subcut q 4h regularly, and PRN
- Lorazepam: 1 to 4 mg SL or subcut q 4h regularly, and PRN
- With or without Methotrimeprazine: 10 to 50 mg subcut q 4h, and PRN

**DRUGS NOT RECOMMENDED FOR PALLIATIVE SEDATION THERAPY**

**Opioids** alone do not provide adequate sedation. Trying to achieve sedation with opioids is very likely to produce neuroexcitatory adverse effects such as myoclonus or agitated delirium.

They **do have a role as analgesics** and are frequently used concurrently with PST.<sup>74</sup> During PST, as with patients under general anaesthesia, pain is still registered within the central nervous system, even if the patient is not consciously aware of, or able to indicate it. Thus, previously prescribed opioid medications must be continued once PST is initiated.
Increasing pain and analgesic requirement may be expected due to disease progression and drug tolerance. However, any increase of opioid doses in a sedated patient should be supported by careful document of signs of pain.\textsuperscript{(117)} Signs of pain in the sedated patient may include, tearing, moaning, tachycardia, tachypnea, hypertension, and movement.

\textbf{Thiopental} is not recommended as it is a common drug used for physician-assisted suicide in those jurisdictions where it is practiced. Its use in PST could be misinterpreted.
REFERENCES

Information was compiled using the CINAHL, Medline (1996 to December 2009) and Cochrane DSR, ACP Journal Club, DARE and CCTR databases, limiting to reviews / systematic reviews, clinical trials, case studies and guidelines / protocols using ‘refractory / intractable symptoms / suffering’ terms, as well as ‘palliative / terminal sedation’ terms in conjunction with palliative / hospice / end of life / dying. Palliative care textbooks mentioned in generated articles were hand searched. Articles not written in English were excluded.


84. Thurston TA, Williams CGA, Foshee SL. Reversal of a paradoxical reaction to midazolam with flumanzenil. Anaesthesia Analgesia. 1996; 83:192.


92. Lorazepam Parenteral Drug Therapy Manual monograph. Fraser Health [Internet] [cited 2008 Dec 29]. Available from:


96. Methotrimeprazine Parenteral Drug Therapy Manual monograph. Fraser Health [Internet] [cited 2008 Dec 29]. Available from:


100. Phenobarb Monograph Clinical Pharmacology. [Internet] [cited 2006 May 16]. Accessed from: http://cp.gms (subscription required)


102. Personal communication Vita Barakova Sandoz Medical Information Specialist March 5; 2008.


110. Fraser Health Hospice Palliative Care. Guidelines for the use of continuous subcutaneous infusions (CSCI) and the medications and combinations that can be administered via CSCI. [Internet]. 2007 [cited 2009 Jan 2]. Available from: http://fhpulse/clinical_support_services/pharmacy/policies_pdtm_ppos_forms/Documents/palliative%20care%20guideline%20csci.pdf


Guide development members identified no conflict of interest. No external funding was received for the development of this guide.
APPENDIX A: SELECTION AND DUTIES OF THE SUBSTITUTE DECISION MAKER

To obtain substitute consent to provide major or minor health care to an adult, a health care provider must choose the first, in listed order, of the following who is available and qualifies (see below).

1. A court-appointed Committee of Person/Personal Guardian: Under the Patients Property Act\(^{(124)}\) (http://www.bclaws.ca/EPLibraries/bclaws_new/document/ID/freeside/00_96349_01), the court may have appointed a committee for an adult who is incapable of making health care decisions.

2. A representative: An adult may, when able to do so, have planned for their future by making a Representation Agreement (section 9 agreement is required for consent to life sustaining treatment) under the Representation Agreement Act\(^{(125)}\) (http://www.bclaws.ca/EPLibraries/bclaws_new/document/ID/freeside/00_96405_01) authorizing a representative to make health care decisions on their behalf if they were unable to make their own decisions.

3. Advance Directive: This needs to be valid and relevant to the health care. If no Representative is appointed, it can stand alone and no TSDM needs to be appointed.

4. A Temporary Substitute Decision Maker: If there is no representative or court-appointed committee of Person/personal guardian, under the Health Care (Consent) and Care Facility (Admission) Act\(^{(80)}\) (http://www.bclaws.ca/EPLibraries/bclaws_new/document/ID/freeside/00_96181_01) a health care provider must choose the nearest relative as ranked below:
   - The adult's spouse (common law, same gender);
   - The adult's children (equally ranked);
   - The adult's parents (equally ranked);
   - The adult's brothers or sisters (equally ranked);
   - The adult's grandparent (equally ranked);
   - The adult's grandchild (equally ranked);
   - Anyone else related by birth or adoption to the adult;
   - A close friend of the adult;
   - A person related immediately to the adult by marriage;
   - Another person appointed by Public Guardian and Trustee.

When no one from the ranked list of substitute decision makers is available or qualified, or there is a dispute between who to appoint that cannot be resolved, the health care provider must contact a Health Care Decisions Consultant at the Public Guardian and Trustee who will appoint or act as TSDM.

To qualify to give, refuse or revoke substitute consent to health care for an adult, a person must:

   a. be at least 19 years of age,
b. have been in contact with the adult during the preceding 12 months,
c. have no dispute with the adult,
d. be capable of giving, refusing or revoking substitute consent, and
e. be willing to comply with the duties below.

DUTIES OF REPRESENTATIVES:

Representatives must:

• Act honestly and in good faith;
• Exercise the care, diligence and skill of a reasonable prudent person; and
• Act within the authority given in the Representation Agreement
• Consult, to a reasonable extent, with the adult to determinate his or her current wishes and
• Comply with those wishes if it is reasonable to do so. Please note, however, that in a section 9 Representation Agreement an adult may provide that the Representative need only comply with any instructions or wishes the adult expressed while capable.

DUTIES OF TEMPORARY SUBSTITUTE DECISION MAKERS:

Temporary Substitute Decision Makers:

• A person chosen to give or refuse substitute consent to health care for an adult must be 19 years of age or older, have had communication within the last 12 months with the patient and not be in dispute with the patient. Before giving or refusing substitute consent, the TSDM(s) must consult to the greatest extent possible:
  a) with the adult, and
  b) if the person chosen under section 16 is a person authorized by the Public Guardian and Trustee, with any friend or relative of the adult who asks to assist, and
  c) comply with any instructions or wishes the adult expressed while he or she was capable.
• If the adult's instructions or wishes are not known, the person chosen must decide to give or refuse consent:
  a) on the basis of the adult's known beliefs and values, or
  b) in the adult's best interests, if his or her beliefs and values are not known.
• When deciding whether it is in the adult’s best interests to give, refuse or revoke substitute consent, the person chosen must consider
  a) the adult's current wishes,
  b) whether the adult's condition or well-being is likely to be improved by the proposed health care,
  c) whether the adult's condition or well-being is likely to improve without the proposed health care,
  d) whether the benefit the adult is expected to obtain from the proposed health care is greater than the risk of harm, and
e) whether a less restrictive or less intrusive form of health care would be as beneficial as the proposed health care
**APPENDIX B: RICHMOND AGITATION SEDATION SCALE (RASS)**

<table>
<thead>
<tr>
<th>TERM</th>
<th>SCORE</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>+4</td>
<td>Combative</td>
<td>Overly combative or violent. Immediate danger to staff.</td>
</tr>
<tr>
<td>+3</td>
<td>Very agitated</td>
<td>Pulls/removes tubes or catheters. Has aggressive behavior toward staff.</td>
</tr>
<tr>
<td>+2</td>
<td>Agitated</td>
<td>Frequent non-purposeful movement.</td>
</tr>
<tr>
<td>+1</td>
<td>Restless</td>
<td>Anxious or apprehensive but movements not aggressive or vigorous</td>
</tr>
<tr>
<td>0</td>
<td>Alert and calm</td>
<td></td>
</tr>
<tr>
<td>-1</td>
<td>Drowsy</td>
<td>Not fully alert, but has sustained (greater than 10 sec) awakening with eye contact to voice.</td>
</tr>
<tr>
<td>-2</td>
<td>Light sedation</td>
<td>Briefly (less than 10 sec) awakens with eye contact to voice.</td>
</tr>
<tr>
<td>-3</td>
<td>Moderate sedation</td>
<td>Any movement (but no eye contact) to voice.</td>
</tr>
<tr>
<td>-4</td>
<td>Deep sedation</td>
<td>No response to voice, but any movement to physical stimulation.</td>
</tr>
<tr>
<td>-5</td>
<td>Unrousable</td>
<td>No response to voice or physical stimulation.</td>
</tr>
</tbody>
</table>

**PROCEDURE FOR RASS ASSESSMENT**

<table>
<thead>
<tr>
<th>STEP</th>
<th>PROCEDURE</th>
<th>SCORE</th>
</tr>
</thead>
</table>
| 1    | Observe patient  
  • Patient is alert, restless, or agitated  
  If not alert, state patient's name and say to open eyes and look at speaker.  
  • Patient awakens with sustained eye opening and eye contact  
  • Patient awakens with eye opening and eye contact, but not sustained  
  • Patient has any movement in response to voice but no eye contact | 0 to +4 |
| 2    | If patient does not respond to voice, physically stimulate patient by shaking shoulder and/or rubbing sternum*:  
  • Patient has any movement to physical stimulation  
  • Patient has no response to any stimulation | -1 to -5 |

* Rubbing the sternum is not appropriate for palliative care patient assessment, and is not recommended.